|
MY139563A
(en)
*
|
2002-09-04 |
2009-10-30 |
Bristol Myers Squibb Co |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
|
US7579360B2
(en)
|
2005-06-09 |
2009-08-25 |
Bristol-Myers Squibb Company |
Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
EP2591675A1
(en)
|
2006-11-27 |
2013-05-15 |
H. Lundbeck A/S |
Heteroaryl amide derivatives
|
|
EA200970931A1
(ru)
|
2007-04-10 |
2010-04-30 |
Х. Лундбекк А/С |
Аналоги гетероариламидов
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US8338450B2
(en)
|
2007-09-21 |
2012-12-25 |
Lupin Limited |
Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
|
|
WO2009126861A2
(en)
|
2008-04-11 |
2009-10-15 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as dgat1 inhibitors
|
|
WO2009126624A1
(en)
|
2008-04-11 |
2009-10-15 |
Bristol-Myers Squibb Company |
Triazolo compounds useful as dgat1 inhibitors
|
|
RU2478636C2
(ru)
|
2008-08-05 |
2013-04-10 |
Дайити Санкио Компани, Лимитед |
ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДИН-2-ОНА, ОБЛАДАЮЩИЕ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ
|
|
EP2417135A1
(en)
*
|
2009-04-07 |
2012-02-15 |
Schering Corporation |
Substituted triazolopyridines and analogs thereof
|
|
MY153913A
(en)
*
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
WO2010146597A1
(en)
|
2009-06-18 |
2010-12-23 |
Lupin Limited |
2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
|
|
RS56410B1
(sr)
*
|
2009-07-27 |
2018-01-31 |
Gilead Sciences Inc |
Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
|
|
EP2509952A1
(en)
*
|
2009-12-08 |
2012-10-17 |
Boehringer Ingelheim International GmbH |
Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
NZ604478A
(en)
|
2010-07-02 |
2014-12-24 |
Gilead Sciences Inc |
Fused heterocyclic compounds as ion channel modulators
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
CA2822357A1
(en)
|
2010-12-22 |
2012-06-28 |
Abbvie Inc. |
Hepatitis c inhibitors and uses thereof
|
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
|
EP2691392A1
(en)
*
|
2011-03-31 |
2014-02-05 |
EMBLEM Technology Transfer GmbH |
Imidazo [1,2-a]pyridine compounds for use in therapy
|
|
ES2785475T3
(es)
|
2011-05-10 |
2020-10-07 |
Gilead Sciences Inc |
Compuestos heterocíclicos fusionados como moduladores de canales iónicos
|
|
NO3175985T3
(enExample)
|
2011-07-01 |
2018-04-28 |
|
|
|
TWI478908B
(zh)
|
2011-07-01 |
2015-04-01 |
Gilead Sciences Inc |
作為離子通道調節劑之稠合雜環化合物
|
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
BR112015000675B1
(pt)
*
|
2012-07-13 |
2022-07-12 |
UCB Biopharma SRL |
Derivados de imidazopiridina como moduladores da atividade de tnf
|
|
US20150297573A1
(en)
|
2012-10-24 |
2015-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
JP6091603B2
(ja)
*
|
2013-03-29 |
2017-03-08 |
帝人ファーマ株式会社 |
ピラゾール誘導体
|
|
AU2014306867B2
(en)
|
2013-08-12 |
2017-10-26 |
Genentech, Inc. |
Compositions and method for treating complement-associated conditions
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
NZ723203A
(en)
|
2014-02-13 |
2020-08-28 |
Incyte Corp |
Cyclopropylamines as lsd1 inhibitors
|
|
PH12020552066A1
(en)
|
2014-02-13 |
2022-05-11 |
Incyte Corp |
Cyclopropylamines as lsd1 inhibitors
|
|
US9493442B2
(en)
|
2014-02-13 |
2016-11-15 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
US10179821B2
(en)
|
2014-05-01 |
2019-01-15 |
Genentech, Inc. |
Anti-factor D antibodies
|
|
US9695180B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
|
|
TWI687419B
(zh)
|
2014-07-10 |
2020-03-11 |
美商英塞特公司 |
作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
|
|
US9695167B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
|
|
WO2016007727A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
CN105503877A
(zh)
|
2014-09-24 |
2016-04-20 |
和记黄埔医药（上海）有限公司 |
咪唑并哒嗪类化合物及其用途
|
|
EP3197870B1
(en)
|
2014-09-25 |
2020-08-19 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
ES2805743T3
(es)
|
2015-03-24 |
2021-02-15 |
Inst Nat Sante Rech Med |
Método y composición farmacéutica para uso en el tratamiento de la diabetes
|
|
TWI714567B
(zh)
|
2015-04-03 |
2021-01-01 |
美商英塞特公司 |
作為lsd1抑制劑之雜環化合物
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
WO2016168540A1
(en)
|
2015-04-15 |
2016-10-20 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
LT3334709T
(lt)
|
2015-08-12 |
2025-03-10 |
Incyte Holdings Corporation |
Lsd1 inhibitoriaus druskos
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
*
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017070089A1
(en)
|
2015-10-19 |
2017-04-27 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US10654932B2
(en)
|
2015-10-30 |
2020-05-19 |
Genentech, Inc. |
Anti-factor D antibody variant conjugates and uses thereof
|
|
KR20240113606A
(ko)
|
2015-11-16 |
2024-07-22 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
RS63762B1
(sr)
|
2015-11-19 |
2022-12-30 |
Incyte Corp |
Heterociklična jedinjenja kao imunomodulatori
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
EP3390361B1
(en)
|
2015-12-17 |
2022-03-16 |
Incyte Corporation |
N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
|
|
TWI767896B
(zh)
|
2015-12-22 |
2022-06-21 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
|
MX387322B
(es)
|
2016-04-22 |
2025-03-18 |
Incyte Corp |
Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
|
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
ES2905980T3
(es)
|
2016-05-26 |
2022-04-12 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
CN109890819B
(zh)
|
2016-06-20 |
2022-11-22 |
因赛特公司 |
作为免疫调节剂的杂环化合物
|
|
US11352328B2
(en)
|
2016-07-12 |
2022-06-07 |
Arisan Therapeutics Inc. |
Heterocyclic compounds for the treatment of arenavirus
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
EP3484866B1
(en)
|
2016-07-14 |
2022-09-07 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
WO2018044783A1
(en)
|
2016-08-29 |
2018-03-08 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
SMT202200415T1
(it)
|
2016-12-22 |
2022-11-18 |
Incyte Corp |
Derivati di tetraidro imidazo[4,5-c]piridina come induttori di internalizzazione di pd-l1
|
|
US20180179201A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
GEAP202215134A
(en)
|
2016-12-22 |
2022-05-10 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
|
EP3558963B1
(en)
|
2016-12-22 |
2022-03-23 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
WO2018119221A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
|
PL4212529T3
(pl)
|
2018-03-30 |
2025-07-07 |
Incyte Corporation |
Związki heterocykliczne jako immunomodulatory
|
|
JOP20200288A1
(ar)
|
2018-05-11 |
2020-11-11 |
Incyte Corp |
مشتقات تترا هيدرو – إيميدازو[4، 5-c]بيريدين كمعدِّلات مناعية pd-l1
|
|
US12134620B2
(en)
|
2018-08-01 |
2024-11-05 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
US12419865B2
(en)
|
2018-12-06 |
2025-09-23 |
Arisan Therapeutics Inc. |
Compounds for the treatment of arenavirus infection
|
|
TW202115059A
(zh)
|
2019-08-09 |
2021-04-16 |
美商英塞特公司 |
Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
|
|
AR120109A1
(es)
|
2019-09-30 |
2022-02-02 |
Incyte Corp |
Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
|
|
CA3156100A1
(en)
|
2019-09-30 |
2021-04-08 |
Janssen Pharmaceutica Nv |
Radiolabelled mgl pet ligands
|
|
CR20220237A
(es)
|
2019-11-11 |
2022-08-05 |
Incyte Corp |
Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
|
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
|
|
IL302590A
(en)
|
2020-11-06 |
2023-07-01 |
Incyte Corp |
Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
|
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|